J Transl Med
. 2022 Jun 11;20(1):268. doi: 10.1186/s12967-022-03461-0.
Treatments of chronic fatigue syndrome and its debilitating comorbidities: a 12-year population-based study
Kam-Hang Leong # 1 2, Hei-Tung Yip # 3, Chien-Feng Kuo # 1 4 5, Shin-Yi Tsai 6 7 8 9 10Affiliations expand
- PMID: 35690765
- DOI: 10.1186/s12967-022-03461-0
For example, if they're allowed to play in a football game and the players let them score a touchdown, do they know it's just people being nice?
My stepdad is a addiction specialist/physiatrist and says the only uses of weed are to treat these 2 conditions. I doubt this as I’ve heard a multitude of benefits of medical cannabis but I’m confirming here I guess.
https://www.nature.com/articles/s41575-022-00662-2.epdf?sharing_token=hriFpe2Y5R_BQTQy-jEJV9RgN0jAjWel9jnR3ZoTv0MBUkPNwf7tnbxdolPVCOemmgjUafIdCY6OtCqUUO9GHLP8FHbVqpGXces7SwlXJqljK3P9pfjAq62egn0T7lck7IyuiFEy-FUl8hZKfuQ1sOja_imhpnfhFQWnaYx_lu0%3D [Edit: New link with full text]
Key points
- The pathophysiological mechanisms associated with irritable bowel syndrome (IBS) are only partially understood; this hampers the development of targeted therapeutic strategies.
- Genetic research can reveal actionable pathways, but findings have generally been scarce in IBS because genetic investigations have been small scale and based on single-gene approaches that have highlighted only a few putative risk genes related to serotonergic mechanisms, carbohydrate digestion or ion channels.
- Large-scale, biobank-wide genome-wide association studies (GWAS) that focused on IBS and endophenotypic proxies of gut motility have been reported, and have led to the identification of the first set of unequivocal risk loci.
- These loci contain several genes relevant to pathways and cell types implicated in the central and enteric nervous system activities, neurotransmitter signalling and enteric motor neuron function; these findings offer avenues for testing novel therapeutic strategies.
- The genetic architecture of IBS identified to date through GWAS often seems to be shared with comorbid mood disorders and anxiety, which is consistent with the reported efficacy of psychotropic and cognitive therapies in IBS.
- Polygenic scores derived from GWAS data enabled the identification of individuals at increased risk of IBS in the studied cohorts and could be further refined and validated in independent translational studies.
The pathophysiology of irritable bowel syndrome (IBS) is multifactorial and probably involves genetic predisposition and the effect of environmental factors. Unlike other gastrointestinal diseases with a heritable component, genetic research in IBS has been scarce and mostly characterized by small underpowered studies, leading to inconclusive results. The availability of genomic and health-related data from large international c
... keep reading on reddit ➡
A paper published in BMJ, late last year, from the University of Hong Kong, documented a case of Ramsay Hunt syndrome (RHS) following COVID-19 vaccination. Below is a snippet from the study, with details about the case and the possible etiology following the vaccination, along with rationale for why some Bell's Palsy cases, which were observed more frequently than RHS following the vaccine could actually be misdiagnosed RHS cases:
>We recently diagnosed Ramsay Hunt syndrome (RHS) in a 37- year- old previously healthy man. Two days after his first dose of the Pfizer- BioNTech (BNT162b2) vaccine, he noticed fever and a pain in the right ear. Vesicles were then developed in his right ear and canal, together with vertigo, tinnitus and loss of hearing. He complained of facial palsy, tongue numbness and dysgeusia. On examination, he had grade 4 right facial nerve palsy of the lower motor neuron type with right sensorineural hearing loss (figure 1A). There were no other neurological deficits. Vesicles with serous discharge were found over the right concha and external auditory canal (figure 1B). A swab of the exudate was positive for varicella- zoster DNA on PCR, while throat saliva was negative for SARS- COV- 2. A CT scan of the brain was normal. The diagnosis was RHS leading to peripheral facial nerve palsy, vestibulocochlear neuropathy and glossopharyngeal somatic sensory neuropathy. As his symptoms developed 2 days after vaccination, we suspected the vaccination triggered RHS. This would be the first reported case of RHS after COVID- 19 vaccination.
>Bell’s palsy is the most common cause of an acute onset peripheral facial palsy. Some cases were attributed to the reactivation of herpes- simplex virus (HSV) and varicella- zoster virus (VZV). The former is always underdiagnosed. However, the blisters of herpes zoster (HZ) allow a diagnosis to be made clinically. Reactivation of the VZV at the facial nerve leads to RHS type 2 (herpes- zoster oticus). However, there are also cases where RHS may manifest without the skin lesions such that it cannot be differentiated from Bell’s palsy without PCR or antibody titre testing.3
>HZ is associated with COVID- 19 vaccination. The US Vaccine Adverse Event Reporting System (VAERS) reported 232 HZ- related adverse events among COVID- 19 vaccines among 1653 reports of vaccine- related complications since July 1990. All reported cases so far affected other dermato
... keep reading on reddit ➡https://onlinelibrary.wiley.com/doi/10.1111/apt.17182
Abstract
Background: Low-grade immune activation in the gut is a potential treatment target in irritable bowel syndrome (IBS).
Aims: To determine improvement in IBS symptoms after mesalazine treatment, and the utility of measures of immune activity in the rectal mucosa METHODS: This was a randomised, double-blind, placebo-controlled, parallel-arm, multicentre trial in subjects with IBS (Rome III criteria), with an eight-week treatment period of mesalazine 2400 mg or plcebo once-daily. The primary endpoint was the global assessment of satisfactory relief of IBS symptoms in ≥50% of weeks during intervention. IBS symptoms were also measured with the IBS severity scoring system; immune activity was measured by mucosal patch technology. A post hoc meta-analysis of randomised placebo-controlled trials of mesalazine in IBS was added.
Results: Of 181 included patients, 91 received mesalazine and 90 received placebo. The primary endpoint was met by 32 (36%) patients after mesalazine and 27 (30%) after placebo (p = 0.40). There were no differences in response rates related to IBS subtype or post-infection symptom onset. More reduction of abdominal bloating was noted in the mesalazine group (p = 0.02). The meta-analysis showed no effect of mesalazine on IBS symptoms. No mucosal patch technology measure could predict response to mesalazine, and found no differences in the effects of intervention on levels of immune markers.
Conclusions: Mesalazine is ineffective in reducing IBS symptoms. Rectal measures of immune activity by the mucosal patch technology cannot predict a higher chance of response to mesalazine.
I am struggling with RLS since young and sometimes it comes and goes. I have no idea how to describe the feeling of having restless legs. It feels irritating? It can also occur at any time of the day. When it strikes day time, I have the strong urge to move a lot and shake my legs violently but it is not nice to be shaking your legs in a meeting. During night time, it affects my sleep a lot as any position is uncomfortable. Taking the plane is the worst as you cannot move much. If you have RLS, please share your experience and how you cope with it!
A possible treatment for visual snow syndrome - noninvasive vagus nerve stimulation ?
https://3002a505d4f8666b1f13-6d0524d9c8a5052ce15209ae3ecb39a3.ssl.cf1.rackcdn.com//1331552-1590438434.pdf
